呼吸系统疾病疗法研发商Celea Therapeutics完成1.8亿美元融资，以推进Deupirfenidone成为治疗特发性肺纤维化（IPF）的潜在新标准疗法-动脉网

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PureTech Health 等信源发布 2026-07-02 14:13



可切换为仅中文







PDF Version

PDF 版本

RNS Number : 7006K

RNS编号：7006K

PureTech Health PLC

02 July 2026

2026年7月2日

July 2026

2026年7月

PureTech Health plc

PureTech Health 股份有限公司

PureTech Founded Entity

PureTech 创立的实体

Celea Therapeutics Completes

Celea Therapeutics 完成

$180 Million

1.8亿美元

Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

融资推进Deupirfenidone作为治疗特发性肺纤维化（IPF）的潜在新标准疗法

PureTech

纯科技

launches Celea as an independent company backed by a syndicate of top-tier healthcare investors, enabling

推出Celea，作为一家由顶级医疗保健投资者组成的财团支持的独立公司，使

PureTech's

PureTech的

transition to a lean operating model

向精益运营模式转型

PureTech

retains 35.4% ownership of Celea in addition to non-dilutive royalties, milestone payments, and sublicense income, maintaining long-term potential upside

保留对Celea的35.4%所有权，以及非稀释性特许权使用费、里程碑付款和再许可收入，保持长期潜在上行空间

Proceeds enable Celea to initiate SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone as a potential new standard of care

所得资金使Celea能够启动SURPASS-IPF研究，这是特发性肺纤维化（IPF）领域首个头对头III期临床试验，旨在评估deupirfenidone作为潜在新标准疗法的优越性。

PureTech Health plc

PureTech Health 股份有限公司

(LSE: PRTC) ('

（伦敦证券交易所：PRTC）（'

PureTech

纯科技

' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, is pleased to note that its Founded Entity Celea Therapeutics ('Celea') today announced the completion of a

”或“公司”），一家致力于赋予科学生命并将创新转化为价值的枢纽辐射型生物治疗公司，欣然注意到其旗下创立实体Celea Therapeutics（“Celea”）今日宣布完成了一项

$180 million

1.8亿美元

financing. Participants included

融资。参与者包括

RA Capital Management

RA资本管理公司

, Leaps by Bayer, and founder

，拜耳旗下 Leaps 以及创始人

PureTech Health

, alongside a large,

，以及一个大型的

U.S

美国

.-based healthcare-focused fund and a leading sovereign wealth fund.

一家总部位于某地、专注于医疗保健领域的基金，以及一家领先的主权财富基金。

Proceeds from the financing will support the planned early Q3 2026 initiation of the Phase 3 SURPASS-IPF trial of deupirfenidone (LYT-100),

融资所得将用于支持按计划于2026年第三季度初启动deupirfenidone（LYT-100）的III期SURPASS-IPF临床试验，

an investigational next-generation antifibrotic with the potential to serve as a new standard of care for people living with idiopathic pulmonary fibrosis (IPF).

一种在研的下一代抗纤维化药物，有望成为特发性肺纤维化（IPF）患者的新标准治疗方案。

Robert Lyne

罗伯特·莱恩

, Chief Executive Officer of

，首席执行官

PureTech

commented:

评论：

'The completion of Celea's

Celea 的完成

$180 million

1.8亿美元

financing marks a transformative milestone for both

融资对双方而言都是一个具有变革意义的里程碑

PureTech

and Celea. The participation from a distinguished syndicate of leading healthcare investors provides powerful third-party validation of the deupirfenidone program and the significant progress achieved to date, underscoring the meaningful commercial opportunity we collectively believe it represents..

以及Celea。来自知名领先医疗健康投资者组成的银团的参与，为deupirfenidone项目提供了强有力的第三方验证，并肯定了迄今为止取得的重大进展，突显了我们共同相信的其具有意义的商业机会。

With this financing, Celea is now positioned to initiate the first-ever industry-sponsored head-to-head Phase 3 trial in IPF. Success in this pivotal trial has the potential to redefine the treatment landscape, delivering significant benefit for patients and value for shareholders.

凭借此次融资，Celea 现已具备启动特发性肺纤维化（IPF）领域首个由行业赞助的头对头 III 期临床试验的条件。这项关键性试验的成功有望重塑治疗格局，为患者带来显著获益，并为股东创造价值。

This transaction establishes Celea as an independent company with dedicated capital to advance deupirfenidone and a high-quality syndicate to support the company's continued growth. To that end,

本次交易使Celea成为一家独立公司，拥有用于推进deupirfenidone研发的专项资金，以及一个高质量的银团来支持公司的持续增长。为此，

PureTech

纯科技

is reserving

正在预订

$70 million

7000万美元

beyond our

超越我们的

$30 million

3000万美元

participation in this round to support Celea based on our conviction in the deupirfenidone program, especially in light of recent public valuations of late-stage clinical assets in the pulmonary space.

参与本轮投资以支持Celea，基于我们对deupirfenidone项目的坚定信心，尤其是在近期肺部领域后期临床资产公开估值的背景下。

For

对于

PureTech

, the transaction delivers on the strategy we outlined in 2025. By establishing a path for the continued development of deupirfenidone with third-party capital, the transaction enables

，该交易实现了我们在2025年概述的战略。通过为deupirfenidone的持续开发建立一条借助第三方资本的路径，该交易使得

PureTech's

PureTech的

transition to a lean operating model while maintaining meaningful ownership in Celea and significant long-term economic upside.

在向精益运营模式转型的同时，保持对Celea的实质性所有权以及显著的长期经济上行潜力。

More broadly, this milestone reinforces

更广泛地说，这一里程碑强化了

PureTech's

PureTech的

track record of advancing differentiated programs to key value-inflection points and positioning them to attract high-quality, substantial third-party investment. This disciplined approach remains central to our strategy of continuing to create a diversified portfolio with multiple future value drivers, generating innovative medicines for patients and value for shareholders.'.

在推动差异化项目达到关键价值拐点并使其吸引高质量、大规模的第三方投资方面拥有良好的业绩记录。这种严谨的方法仍然是我们战略的核心，旨在继续打造拥有多个未来价值驱动因素的多元化产品组合，为患者提供创新药物，为股东创造价值。

Eric Elenko

埃里克·埃伦科

, Ph.D., President and Co-founder of

，博士，总裁兼联合创始人

PureTech

纯科技

commented:

评论了：

PureTech's

PureTech的

model is to advance differentiated programs to key value-inflection points and establish them as independent companies with the dedicated capital, governance, and strategic focus needed for their next stage of development. Today's financing represents an important milestone in that strategy. We are pleased to welcome this exceptional group of investors and board members as partners in Celea, whose support will be invaluable in positioning Celea for long-term success as it advances deupirfenidone through Phase 3 and beyond.'.

该模式旨在推动差异化项目达到关键的价值拐点，并将其确立为独立公司，配备其下一阶段发展所需的专用资本、治理结构和战略重点。今天的融资代表了这一战略的重要里程碑。我们很高兴欢迎这群杰出的投资者和董事会成员成为Celea的合作伙伴，他们的支持对于将Celea定位为长期成功至关重要，因为Celea正在推进deupirfenidone通过第三阶段及以后的研究。

Consistent with the strategic priorities outlined by

与所概述的战略重点一致

PureTech

纯科技

in 2025, the financing establishes a capital-efficient path forward for the deupirfenidone program, providing a dedicated team and external capital to support the continued development of deupirfenidone, while enabling

在2025年，该融资为deupirfenidone项目确立了一条资本高效的前进路径，提供了专门的团队和外部资金以支持deupirfenidone的持续开发，同时使

PureTech

to retain meaningful ownership and significant non-dilutive economics.

以保持有意义的所有权和显著的非稀释性经济利益。

PureTech

contributed

贡献了

$30 million

3000万美元

in the completed financing and has reserved

在已完成的融资中，并已预留

$70 million

7000万美元

from existing cash resources to potentially support Celea in the future. As previously guided in

从现有现金资源中调配，以在未来潜在地支持Celea。正如先前指引中所述

PureTech's

PureTech的

2025 Annual Report and Accounts,

2025年年度报告及账目，

PureTech

has operational runway at least through the end of 2028, which accounts for the full deployment of the additional

拥有至少持续到2028年底的运营跑道，这 accounted for 额外部署的全部

$70 million

7000万美元

reserved for Celea.

预留给Celea。

Following the completion of the financing,

融资完成后，

PureTech

holds 35.4% of the fully diluted share capital in Celea.

持有Celea完全稀释后股本的35.4%。

[1]

PureTech

纯科技

is also entitled to receive tiered royalties

也有权获得分级版税

[2]

on annual net sales of Celea's products that use the deupirfenidone technology, including:

基于使用去吡非尼酮技术的Celea产品年度净销售额，包括：

1% of annual net sales less than

年净销售额的1%以下

$1 billion

10亿美元

2% of annual net sales equal to or greater than

年净销售额的2%或以上

$1 billion

10亿美元

but less than

但少于

$2 billion

20亿美元

3% of annual net sales equal to or greater than

年净销售额的3%或以上

$2 billion

20亿美元

Additionally,

此外，

PureTech

is entitled to receive up to

有权获得最高

$190 million

1.9亿美元

in aggregate milestone payments in connection with various sales milestones, including:

合计与各项销售里程碑相关的里程碑付款，包括：

$15 million

1500万美元

upon the first commercial sale of a Celea product in

在 Celea 产品首次商业销售时

the United States

美国

;

分号

$25 million

2500万美元

upon the first achievement of

在首次实现

$500 million

5亿美元

in worldwide net sales of all Celea products in a single calendar year;

在一个日历年内，所有Celea产品的全球净销售额；

$50 million

5000万美元

upon the first achievement of

在首次实现

$1 billion

10亿美元

in worldwide net sales of all Celea products in a single calendar year; and

在单个日历年度内，所有Celea产品在全球范围内的净销售额；并且

$100 million

1亿美元

upon the first achievement of

在首次实现

$3 billion

30亿美元

in worldwide net sales of all Celea products in a single calendar year.

在所有Celea产品在一个日历年内的全球净销售额中。

PureTech

is also entitled to receive 20% of sublicense income generated by Celea with respect to the deupirfenidone technology.

也有权获得Celea就deupirfenidone技术所产生的分许可收入的20%。

For related disclosures made in accordance with the

对于根据

英国

Listing Rules, please refer to the accompanying announcement issued by the Company on

上市规则，请参阅本公司发布的随附公告

July 2, 2026

2026年7月2日

, under RNS number 7005K.

，RNS编号为7005K。

The full text of the announcement from Celea is as follows:

Celea发布的公告全文如下：

Celea Therapeutics Announces

Celea Therapeutics 宣布

$180 Million

1.8亿美元

Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

融资推进Deupirfenidone成为治疗特发性肺纤维化（IPF）的潜在新标准疗法

Financing brings together a syndicate of top-tier healthcare investors, including

融资汇聚了一批顶级医疗保健投资者组成的银团，包括

RA Capital Management

RA资本管理

, Leaps by Bayer, and Celea founder

，拜耳旗下的 Leaps，以及 Celea 创始人

PureTech Health

, alongside a large, US-based healthcare-focused fund and a leading sovereign wealth fund

以及一家总部位于美国的大型医疗健康领域基金和一家领先的主权财富基金

Proceeds will enable early Q3 2026 initiation of SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone vs. pirfenidone

所得款项将用于在2026年第三季度初启动SURPASS-IPF研究，这是特发性肺纤维化（IPF）领域首个头对头III期临床试验，旨在评估deupirfenidone相较于吡非尼酮的优效性。

BOSTON

波士顿

，

July 2, 2026

2026年7月2日

Celea Therapeutics

Celea 治疗公司

('Celea' or the 'Company'), a clinical-stage biopharmaceutical company dedicated to advancing transformative treatments for people with serious respiratory diseases, today announced the completion of a

（“Celea”或“公司”），一家致力于推进针对严重呼吸系统疾病患者的变革性疗法的临床阶段生物制药公司，今日宣布完成了一项

$180 million

1.8亿美元

financing. Participants included

融资。参与者包括

RA Capital Management

RA资本管理公司

, Leaps by Bayer, and founder

、拜耳的 Leaps 以及创始人

PureTech Health

(LSE: PRTC), alongside a large,

（伦敦证券交易所：PRTC），以及一个大型、

U.S

美国

.-based healthcare-focused fund and a leading sovereign wealth fund

一家总部位于某地、专注于医疗保健领域的基金和一家领先的主权财富基金

. Proceeds from the financing will support the planned early Q3 2026 initiation of the Phase 3 SURPASS-IPF trial of deupirfenidone (LYT-100),

融资所得将用于支持按计划于2026年第三季度初启动deupirfenidone（LYT-100）的III期SURPASS-IPF临床试验，

an investigational next-generation antifibrotic with the potential to serve as a new standard of care for people living with idiopathic pulmonary fibrosis (IPF).

一种在研的新一代抗纤维化药物，有望成为特发性肺纤维化（IPF）患者的新标准治疗方案。

'People living with IPF continue to face a devastating disease with limited treatment options, and we believe deupirfenidone has the potential to deliver meaningful improvements for patients,' said

“特发性肺纤维化（IPF）患者继续面临着一种治疗选择有限的毁灭性疾病，我们相信deupirfenidone有潜力为患者带来有意义的改善，”

Sven Dethlefs

斯文·德特莱夫斯

, Ph.D., Chief Executive Officer of Celea. 'We are grateful for the support and confidence of this exceptional group of investors, whose commitment enables us to initiate the Phase 3 SURPASS-IPF trial and advance development of deupirfenidone with the speed and focus this community deserves.'

博士，Celea 公司首席执行官。“我们感激这群杰出投资者给予的支持与信任，他们的承诺使我们能够启动 SURPASS-IPF III 期临床试验，并以该患者群体所应得的速度和专注推进 deupirfenidone 的研发。”

'We are delighted to support Celea as it enters this important next stage of development,' said

“我们很高兴在Celea进入这一重要的下一发展阶段时提供支持，”

Laura Stoppel

劳拉·斯托佩尔

, Ph.D., Partner at

，博士，合伙人

RA Capital Management

RA资本管理

. 'The compelling results generated to date with deupirfenidone and the Company's bold Phase 3 SURPASS-IPF trial represent a differentiated opportunity to meaningfully change the treatment landscape in IPF. Supported by a seasoned team with a demonstrated track record of successfully advancing innovative medicines, Celea is exceptionally well positioned to execute on its strategy of unlocking the full potential of deupirfenidone for patients.'.

“迄今为止，deupirfenidone 取得的令人瞩目的成果，以及公司大胆开展的 III 期 SURPASS-IPF 临床试验，代表了在特发性肺纤维化（IPF）治疗领域实现差异化突破、切实改变治疗格局的重要机遇。Celea 拥有一支经验丰富的团队，其在成功推进创新药物研发方面有着经证实的卓越记录，因此公司在执行其充分释放 deupirfenidone 对患者全部潜力的战略方面处于极为有利的地位。”

The planned pivotal Phase 3 SURPASS-IPF trial is a global, randomized, double-blind, head-to-head trial directly comparing deupirfenidone 825 mg TID to pirfenidone 801 mg TID in adults with IPF who are not on background therapy. The primary efficacy endpoint is the change from baseline in absolute forced vital capacity at week 52, which will assess the superiority of deupirfenidone compared with pirfenidone.

计划中的关键性III期SURPASS-IPF试验是一项全球性、随机、双盲、头对头试验，直接比较deupirfenidone 825 mg TID与pirfenidone 801 mg TID在未接受背景治疗的特发性肺纤维化（IPF）成人患者中的疗效。主要有效性终点为第52周时绝对用力肺活量（FVC）相对于基线的变化，旨在评估deupirfenidone相较于pirfenidone的优效性。

Celea expects to initiate the Phase 3 SURPASS-IPF trial in early Q3 2026..

Celea预计将于2026年第三季度初启动SURPASS-IPF III期临床试验。

About Deupirfenidone (LYT-100)

关于Deupirfenidone（LYT-100）

Deupirfenidone (LYT-100) is in development as a potential new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) and has been granted Orphan Drug Designation

Deupirfenidone（LYT-100）正在开发中，有望成为治疗特发性肺纤维化（IPF）的新标准疗法，并已获得孤儿药资格认定。

from the

从

U.S. Food and Drug Administration

美国食品药品监督管理局

and

和

European Commission

欧盟委员会

. It is an investigational next-generation antifibrotic and a deuterated form of pirfenidone, one of three FDA-approved therapies for IPF. The uptake of and adherence to approved antifibrotics has historically been limited by a tradeoff between modest efficacy and tolerability, and only ~25% of people with IPF in the .

。这是一种在研的下一代抗纤维化药物，也是吡非尼酮的氘代形式，而吡非尼酮是美国食品药品监督管理局（FDA）批准的三种特发性肺纤维化（IPF）治疗药物之一。历史上，由于疗效有限与耐受性之间的权衡，获批抗纤维化药物的使用和依从性一直受到限制，在……中仅有约25%的IPF患者。

U.S

美国

. had ever received treatment as of 2019.

截至2019年曾接受过治疗。

[3]

Deupirfenidone may overcome these limitations.

Deupirfenidone 可能克服这些局限性。

In the

在

global Phase 2b ELEVATE IPF trial,

全球2b期ELEVATE特发性肺纤维化（IPF）临床试验，

published in

发表于

The

这

American Journal of Respiratory and Critical Care Medicine

美国呼吸与重症监护医学杂志

(

（

AJRCCM), deupirfenidone

AJRCCM），去吡非尼酮

demonstrated the potential to stabilize lung function decline over at least 26 weeks as a monotherapy while maintaining a favorable safety and tolerability profile. Initial data from the open-label extension study suggest this effect may be sustained through at least 52 weeks. These findings support the potential for deupirfenidone to offer a meaningful advance for people living with this progressive and deadly disease.

作为单药治疗，deupirfenidone 在至少 26 周内展现出稳定肺功能下降的潜力，同时保持良好的安全性和耐受性。来自开放标签扩展研究的初步数据表明，这一效果可能至少持续至 52 周。这些发现支持 deupirfenidone 有望为罹患这种进行性且致命疾病的患者带来具有临床意义的进展。

Beyond IPF, deupirfenidone may also address multiple underserved fibrotic conditions, including progressive fibrosing interstitial lung diseases. .

除特发性肺纤维化（IPF）外，deupirfenidone 还可能用于治疗多种未被充分满足需求的纤维化疾病，包括进行性纤维化性间质性肺病。

About Idiopathic Pulmonary Fibrosis (IPF)

关于特发性肺纤维化（IPF）

Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal lung disease characterized by irreversible scarring of lung tissue that leads to a steady decline in lung function. Median survival following diagnosis is estimated to be two to five years,

特发性肺纤维化（IPF）是一种罕见、进行性且致命的肺部疾病，其特征为肺组织出现不可逆的瘢痕形成，导致肺功能持续下降。确诊后的中位生存期估计为两至五年，

[4]

and currently there is no cure.

目前尚无治愈方法。

About

关于

Celea Therapeutics

Celea 治疗公司

Celea Therapeutics

is dedicated to advancing transformative treatments for people with serious respiratory diseases. Drawn from the Latin word for 'sky,' the name reflects the company's mission to rise above the status quo and deliver therapies that change lives. Celea's lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate with the potential to set a new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. Celea was founded by .

致力于推进针对严重呼吸系统疾病的变革性疗法。其名称源自拉丁语中意为“天空”的词汇，彰显了公司超越现状、提供改变生命的疗法的使命。Celea 的核心项目 deupirfenidone（LYT-100）是一款具备进入 III 期临床试验条件的治疗候选药物，有望为特发性肺纤维化（IPF）及其他纤维化肺病确立新的治疗标准。Celea 由……创立。

PureTech Health plc

PureTech Health 股份有限公司

(LSE: PRTC), a hub-and-spoke biotherapeutics company dedicated to giving life to science. For more information, please visit

（伦敦证券交易所代码：PRTC），一家致力于赋予科学生命的枢纽辐射型生物治疗公司。欲了解更多信息，请访问

www.celeatx.com

。

About

关于

PureTech Health

is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received .

是一家采用中心辐射型模式的生物治疗公司，致力于赋予科学生命力，并将创新转化为价值。我们通过一种经过验证且资本高效的研发模式实现这一目标，专注于那些药理学机制已获验证、并具有尚未开发的潜力以满足重大患者需求的机会。该策略已催生数十种治疗候选药物，其中包括三种已获得

U.S

美国

. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

FDA 批准。通过识别、塑造和降低这些高确定性资产的风险，并借助外部资本支持的专用架构将其规模化，我们加速了这些资产惠及患者的进程，同时为股东创造可持续的价值。

For more information, visit

欲了解更多信息，请访问

www.puretechhealth.com

or connect with us on

或通过以下方式联系我们

领英

and X (formerly Twitter) @puretechh.

以及 X（前身为 Twitter）@puretechh。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示说明

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to the planned development of deupirfenidone, .

本新闻稿包含根据1995年《私人证券诉讼改革法》定义的前瞻性陈述。本新闻稿中所有不涉及历史事实的陈述均应视为前瞻性陈述，包括但不限于与deupirfenidone计划开发相关的陈述。

PureTech's

PureTech的

reservation of capital to support Celea in the future, our operating runway, and our and Celea's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended .

预留资本以在未来支持Celea、我们的运营续航能力，以及我们与Celea的未来前景、发展和战略。前瞻性陈述基于当前预期，并受已知和未知的风险、不确定性及其他重要因素的影响，这些因素可能导致实际结果、表现和成就与当前预期存在重大差异，包括但不限于我们在截至年度的20-F表格年度报告中“风险因素”标题下所述的那些风险、不确定性和其他重要因素。

December 31, 2025

2025年12月31日

, filed with the

，提交给

SEC

美国证券交易委员会

and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release.

以及在我们的其他监管文件中。这些前瞻性陈述基于对公司当前及未来业务战略及其未来运营环境的假设。每项前瞻性陈述仅截至本新闻稿发布之日有效。

Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise..

除法律和监管要求另有规定外，我们不承担任何因新信息、未来事件或其他原因而更新或修订这些前瞻性陈述的义务。

Contact:

联系方式：

PureTech

Public Relations

公共关系

publicrelations@puretechhealth.com

Investor Relations

投资者关系

IR@puretechhealth.com

英国

/EU Media

/欧盟媒体

Ben Atwell

本·阿特韦尔

，

Rob Winder

罗布·温德

+44 (0) 20 3727 1000

puretech@fticonsulting.com

U.S

美国

. Media

媒体

Justin Chen

贾斯汀·陈

jchen@tenbridgecommunications.com

[1]

PureTech

纯科技

ownership interest calculated as of

截至计算的所有权权益

July 1, 2026

2026年7月1日

。

[2]

Celea will pay

Celea 将支付

PureTech

tiered royalties on annual net sales of Celea's products that use the deupirfenidone technology until the later of the last-to-expire patent or ten (10) years from the first commercial sale of such Celea product. These royalty amounts are potentially subject to customary reductions based on future events..

对使用deupirfenidone技术的Celea产品年度净销售额收取分级特许权使用费，直至以下较晚者为止：最后一项到期专利的到期日，或此类Celea产品首次商业销售之日起十（10）年。这些特许权使用费金额可能根据未来事件按惯例进行减免。

[3]

Dempsey,

邓普西，

T. M

., Payne, S., Sangaralingham, L., Yao, X., Shah, N. D., & Limper, A. H. (2021). Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. Annals of the

., Payne, S., Sangaralingham, L., Yao, X., Shah, N. D., & Limper, A. H. (2021). 特发性肺纤维化患者抗纤维化药物吡非尼酮和尼达尼布的采用情况。《内科年鉴》

American Thoracic Society

美国胸科学会

, 18(7), 1121-1128.

，18(7)，1121-1128。

[4]

Fisher, M., Nathan, S. D., Hill, C., Marshall, J.,

费舍尔，M.，纳森，S.D.，希尔，C.，马歇尔，J.，

Dejonckheere

德容凯尔

, F., Thuresson, P., & Maher,

，F.，图雷松，P.，和马赫

T. M

. (2017). Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis.

.（2017年）。预测吡非尼酮在特发性肺纤维化中的预期寿命。

Journal of Managed Care & Specialty Pharmacy

《管理式医疗与专科药学杂志》

, 23

，23

(3-b Suppl), S17-S24.

(3-b 增刊), S17-S24。

This information is provided by RNS, the news service of the

此信息由RNS，即新闻服务机构提供。

London Stock Exchange

伦敦证券交易所

. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the

RNS 获英国金融行为监管局批准，担任主要信息提供商

United Kingdom

英国

. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact

. 使用及分发本信息可能受相关条款和条件的约束。如需更多信息，请联系

rns@lseg.com

or visit

或访问

www.rns.com

。

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the .

RNS 可能会使用您的 IP 地址来确认您是否遵守条款和条件，分析您如何参与本通讯中包含的信息，并在匿名基础上与他人共享此类分析，作为我们商业服务的一部分。有关 RNS 以及如何的更多信息，请参见。

London Stock Exchange

伦敦证券交易所

use the personal data you provide us, please see our

使用您向我们提供的个人数据，请参阅我们的

隐私政策

。

END

结束

MSCUPUMCMUPQPGG

全球产业链接平台

重庆市渝北区金星科技大厦A区5楼512室